Cagrilintide
Cagrilintide represents the bleeding-edge of dual-pathway metabolic intervention. As an ultra-long-acting synthetic analog of human amylin (a hormone co-secreted with insulin), it bypasses the traditional GLP-1 pathway to radically suppress appetite via a distinctly separate neurological mechanism. Engineered by Novo Nordisk to shatter weight loss plateaus encountered on high-dose GLP-1 monotherapy, it exerts overwhelming synergistic control over gastric motility and severe hyperphagia, driving unprecedented reductions in absolute fat mass.
Quick Stats
Scientific Data
Mechanism of Action
Cagrilintide is a fatty acid-modified long-acting analog of human amylin (islet amyloid polypeptide, IAPP) — a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. Two amino acid substitutions plus a C20 fatty acid chain extend its half-life to ~7 days, enabling once-weekly dosing.
Amylin acts centrally (area postrema, NTS) to reduce glucagon secretion, slow gastric emptying, and suppress appetite via different receptors than GLP-1. This mechanistic complementarity is the rationale for combining cagrilintide with semaglutide (GLP-1 RA) in the CagriSema combination. In SCALE NEXT (cagrilintide 4.5 mg monotherapy), 12.5% weight loss at 24 weeks was observed. Combined with semaglutide (CagriSema), 22.7% weight loss at 68 weeks was achieved in PHASE III.
Source: PMID: 35948058 (CAGRISEMA Phase 2)
Background & History
Cagrilintide (AM833) is a long-acting amylin analog developed by Novo Nordisk. Amylin (islet amyloid polypeptide, IAPP) is a peptide co-secreted with insulin from pancreatic beta cells that plays a critical role in post-prandial satiety. The only previously approved amylin analog was pramlintide (Symlin) — a 37-residue synthetic amylin requiring three daily injections. Cagrilintide overcomes this limitation with half-life extension to approximately 7-8 days via fatty acid chain modification, enabling once-weekly dosing. Clinical development accelerated significantly when Phase 2 CAGRISEMA trial results (2022) showed the cagrilintide + semaglutide combination produced superior weight loss (~15.6%) compared to either agent alone.
Research Use Cases
- ✓Obesity management as part of the CagriSema combination
- ✓Post-prandial glucagon suppression and satiety via amylin pathway
- ✓Weight loss in GLP-1-intolerant or non-responder patients
- ✓Research: amylin receptor biology and CNS satiety circuitry
Dosing Protocol
| Typical Dose | 0.3-4.5 mg/week |
| Frequency | 1× weekly |
| Half-Life | ~7-8 days |
| Common Vial Sizes | 3 mg, 5 mg |
Dosing Protocols
Phase III Protocol
Administration
Expected Timeline
Who Is It For?
Obesity / Weight Loss
EmergingPhase III data shows 22.7% weight loss with CagriSema. Not yet FDA-approved as of 2024.
Reconstitution Example
Safety & Considerations
Investigational drug (not FDA-approved as of 2024). Phase III safety profile similar to amylin analogs — nausea, injection site reactions. Being evaluated in large clinical trials.
Regulatory & Legal Status
In Phase 3 REDEFINE trials as part of Cagrisema combination (with semaglutide)
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Investigational
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Amylin analogs slow gastric emptying — additive effect with GLP-1 agonists (beneficial for weight loss, but increased GI side effect risk). Monitor blood glucose carefully especially in T2D patients — amylin + insulin effects on post-prandial glucose can cause hypoglycemia. Not for use with severe GI disease. Investigational outside of clinical trials.
Synergies & Common Stacks
The definitive synergy — this is the basis of the CagriSema combination. Amylin (cagrilintide) and GLP-1 (semaglutide) activate entirely different receptor systems, producing additive weight loss beyond either alone.
Theoretically complementary — tirzepatide provides GLP-1 + GIP agonism; cagrilintide adds the amylin pathway. This triple-mechanism combination is not yet in trials but represents the next frontier of obesity pharmacotherapy.
Dosing Quick Reference
Frequently Asked Questions
How does cagrilintide differ from GLP-1 agonists like semaglutide?▼
References
- Lau DCW et al. “"Cagrilintide + semaglutide 2.4 mg (CagriSema): Phase III weight loss".” Lancet (2024). PMID: 38733994
Get Cagrilintide from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review